Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
25 hedge funds and large institutions have $101M invested in Achilles Therapeutics in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 30 → 25 (-5)
26% less capital invested
Capital invested by funds: $137M → $101M (-$36.4M)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.78M |
| 2 |
BlackRock
New York
|
+$193K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$21K |
| 4 |
Renaissance Technologies
New York
|
+$17.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$3.78M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$288K |
| 4 |
SCP
Sender Company & Partners
New York
|
-$139K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$137K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RI
26
RTW Investments
New York
| – | -$61K | -12,229 | Closed |
|
|
JF
27
Jump Financial
Chicago,
Illinois
| – | -$55K | -11,000 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5K | -1,000 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | +$75 | +21 | New |
|
ACHL Hedge Fund Activity: Q1 2022 in Review
25 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2022, worth a combined $101M — down 26% from $137M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ACHL and 1 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Point72 Asset Management, adding an estimated $1.78M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $3.78M sold.
- 25 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2022, down from 30 in Q4 2021.
- Funds reported $101M of Achilles Therapeutics stock for Q1 2022, down 26% quarter-over-quarter.
- 1 fund opened new Achilles Therapeutics positions in Q1 2022 and 6 closed out, a net change of -5 holders.
- The largest Achilles Therapeutics buyer in Q1 2022 was Point72 Asset Management, an estimated $1.78M added.
- The largest Achilles Therapeutics seller in Q1 2022 was Perceptive Advisors, an estimated $3.78M sold.
Based on aggregated 13F filings for Q1 2022.